Beta-2-glycoprotein-1 and alpha-1-antitrypsin as urinary markers of renal cancer in von Hippel-Lindau patients

Biomarkers. 2018 Mar;23(2):123-130. doi: 10.1080/1354750X.2016.1269132. Epub 2016 Dec 22.

Abstract

Context: Von Hippel-Lindau disease (VHLD) is a rare inherited neoplastic syndrome. Among all the VHLD-associated tumors, clear cell renal cell carcinoma (ccRCC) is the major cause of death.

Objective: The aim of this paper is the discovery of new non-invasive biomarker for the monitoring of VHLD patients.

Materials and methods: We compared the urinary proteome of VHLD patients, ccRCC patients and healthy volunteers.

Results: Among all differentially expressed proteins, alpha-1-antitrypsin (A1AT) and APOH (beta-2-glycoprotein-1) are strongly over-abundant only in the urine of VHLD patients with a history of ccRCC.

Discussion and conclusion: A1AT and APOH could be promising non-invasive biomarkers.

Keywords: Von Hippel–Lindau disease; beta-2-glycoprotein-1 and alpha-1-antitrypsin; proteomics; renal cancer; urine.

MeSH terms

  • Adult
  • Aged
  • Biomarkers, Tumor / urine*
  • Blotting, Western
  • Carcinoma, Renal Cell / complications
  • Carcinoma, Renal Cell / diagnosis
  • Carcinoma, Renal Cell / urine*
  • Electrophoresis, Gel, Two-Dimensional
  • Female
  • Humans
  • Kidney Neoplasms / complications
  • Kidney Neoplasms / urine*
  • Male
  • Middle Aged
  • Proteome / analysis
  • alpha 1-Antitrypsin / urine*
  • beta 2-Glycoprotein I / urine*
  • von Hippel-Lindau Disease / complications
  • von Hippel-Lindau Disease / urine*

Substances

  • Biomarkers, Tumor
  • Proteome
  • alpha 1-Antitrypsin
  • beta 2-Glycoprotein I